TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34129229

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-Provider Dyads
Number of subjects: 0
Study: 34129237

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 42516

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 42516
Study: 34129363

Group type: EXPERIMENTAL
Intervention: Pulmonary artery pressure sensor implantation
Number of subjects: 1200
Study: 34129366

Group type: EXPERIMENTAL
Intervention: Mechanical circulatory support (including vasopressors, intraaortic balloon pump, and extracorporeal membrane oxygenator)
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Vasopressors (used in 1081 patients, 86.7%)
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pump (used in 314 patients, 25.2%)
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenator (used in 496 patients, 39.8%)
Number of subjects: 1247
Study: 34129486

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 2798

Group type: COMPARATOR
Intervention: Women
Number of subjects: 2798
Study: 34129808

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment, specific dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, specific treatment not available
Number of subjects: 0
Study: 34129837

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with periodontitis
Number of subjects: 0
Study: 34130036

Group type: EXPERIMENTAL
Intervention: Pre-operative assessment of patients
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Post-operative assessment of patients one year after surgery
Number of subjects: 44

Group type: COMPARATOR
Intervention: Asymptomatic controls
Number of subjects: 44
Study: 34130476

Group type: EXPERIMENTAL
Intervention: Conscious Sedation
Number of subjects: 0

Group type: COMPARATOR
Intervention: General Anesthesia
Number of subjects: 0
Study: 34130477

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 0
Study: 34130554

Group type: EXPERIMENTAL
Intervention: Solution-Focused Brief Therapy
Number of subjects: 30
Study: 34130709

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS) with nutritional counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nutritional counseling alone
Number of subjects: 0
Study: 34130731

Group type: EXPERIMENTAL
Intervention: Early combination (EC) therapy
Number of subjects: 537

Group type: COMPARATOR
Intervention: Metformin monotherapy (MET)
Number of subjects: 537
Study: 34130756

Group type: EXPERIMENTAL
Intervention: Intervention group received estimated maximum oxygen uptake (VO2 max) assessment.
Number of subjects: 1315

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 1315

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1315
Study: 34131041

Group type: EXPERIMENTAL
Intervention: Olaparib in combination with weekly carboplatin plus paclitaxel
Number of subjects: 35
Study: 34131047

Group type: EXPERIMENTAL
Intervention: Youth with IGT or recently diagnosed type 2 diabetes (drug naive)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Adults with impaired glucose tolerance (IGT) or recently diagnosed type 2 diabetes (drug naive)
Number of subjects: 416
Study: 34131423

Group type: EXPERIMENTAL
Intervention: TAK-003 (tetravalent dengue vaccine)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 34131623

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 110
Study: 34131821

Group type: EXPERIMENTAL
Intervention: HIPEC with gemcitabine administered at 1000 mg/m²
Number of subjects: 16
Study: 34131914

Group type: EXPERIMENTAL
Intervention: Magnetic seizure therapy (MST)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 65
Study: 34132071

Group type: EXPERIMENTAL
Intervention: Intravenous administration of high-dose selenium (2,000 μg/day)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 68
Study: 34132224

Group type: EXPERIMENTAL
Intervention: Isolated limb perfusion (ILP) with melphalan
Number of subjects: 60
Study: 34132642

Group type: EXPERIMENTAL
Intervention: Directly Observed Therapy (DOT) via mobile health application carried out by community workers.
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Mobile health application for data collection and monitoring framework.
Number of subjects: 236
Study: 34132698

Group type: EXPERIMENTAL
Intervention: Fenestrated-branched endovascular aortic repair (FB-EVAR)
Number of subjects: 430
Study: 34133209

Group type: EXPERIMENTAL
Intervention: Germline genotype-directed therapy
Number of subjects: 11947

Group type: EXPERIMENTAL
Intervention: Germline LP/P variant
Number of subjects: 11947

Group type: EXPERIMENTAL
Intervention: Germline sequence analysis
Number of subjects: 11947
Study: 34134507

Group type: EXPERIMENTAL
Intervention: Hypotension during endovascular therapy in patients with no PComA
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Hypotension during endovascular therapy in patients with PComA
Number of subjects: 148
Study: 34134520

Group type: EXPERIMENTAL
Intervention: Niacin-statin combination therapy
Number of subjects: 244

Group type: COMPARATOR
Intervention: Statin monotherapy
Number of subjects: 244
Study: 34134744

Group type: EXPERIMENTAL
Intervention: Digitally supported care management programme
Number of subjects: 500

Group type: COMPARATOR
Intervention: Usual care (wait-list control group)
Number of subjects: 500
Study: 34134788

Group type: EXPERIMENTAL
Intervention: painTRAINER (internet-based pain coping skills training program)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: painTRAINER users (those who accessed the program)
Number of subjects: 60

Group type: COMPARATOR
Intervention: wait list control group
Number of subjects: 60
Study: 34134830

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBGT)
Number of subjects: 58
Study: 34134832

Group type: EXPERIMENTAL
Intervention: Memory Support Treatment Provider Checklist
Number of subjects: 84
Study: 34135022

Group type: EXPERIMENTAL
Intervention: Net endogenous acid production using food frequency questionnaires
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Net endogenous acid production using urinary excretion
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Higher dietary acid load
Number of subjects: 642
Study: 34135053

Group type: EXPERIMENTAL
Intervention: Patient decision aid (PtDA) for 'timely' dementia diagnosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diagnostics as usual from their GPs (before group)
Number of subjects: 0
Study: 34135471

Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients (425 total)
Number of subjects: 1162

Group type: COMPARATOR
Intervention: COVID-19 negative patients (737 total)
Number of subjects: 1162

Group type: EXPERIMENTAL
Intervention: Overall population (COVID-19 positive and negative)
Number of subjects: 1162

Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients
Number of subjects: 1162
Study: 34135566

Group type: EXPERIMENTAL
Intervention: Intravitreal injection guide (IIG)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional dual blade speculum plus surgical caliper (DBS)
Number of subjects: 200
Study: 34135690

Group type: EXPERIMENTAL
Intervention: Intracoronary thrombi aspirated from STEMI patients
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Inflammasome signaling pathway
Number of subjects: 33
Study: 34135843

Group type: EXPERIMENTAL
Intervention: Repeated Mesenchymal Stem Cell Injections
Number of subjects: 0
Study: 34135855

Group type: EXPERIMENTAL
Intervention: Elevated Cardiac Troponin I levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34136023

Group type: COMPARATOR
Intervention: Standard Frontal View (SFV) colonoscopy
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Panoramic View Colonoscopy (PVC)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Both groups (SFV and PVC)
Number of subjects: 421
Study: 34136337

Group type: EXPERIMENTAL
Intervention: Healthy Start/Départ Santé (HS/DS) intervention
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study: 34136501

Group type: EXPERIMENTAL
Intervention: Liraglutide, a glucagon-like peptide-1 receptor agonist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34136542

Group type: EXPERIMENTAL
Intervention: Concomitant impairments of the left and right ventricular myocardial strain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34136782

Group type: EXPERIMENTAL
Intervention: Patiromer at doses ranging from 4.2 to 16.8 g twice daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 60
Study: 34136987

Group type: EXPERIMENTAL
Intervention: MT-8 h and MT-12 h formulations (120 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MT-12 h with a high-fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MT-12 h once-daily for 3 days at three dose levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MM-12 h formulation at two dose levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate release (IR) formulation (120 mg)
Number of subjects: 0
Study: 34137430

Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg every 8 weeks
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Vedolizumab every 4 weeks (model-based simulation)
Number of subjects: 110
Study: 34138447

Group type: EXPERIMENTAL
Intervention: Patients with a current psychiatric disorder
Number of subjects: 245

Group type: COMPARATOR
Intervention: Patients without a current psychiatric disorder
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Patients reporting clinically relevant FCR
Number of subjects: 245
Study: 34138449

Group type: EXPERIMENTAL
Intervention: Remote Electrical Neuromodulation (REN)
Number of subjects: 91
Study: 34138594

Group type: EXPERIMENTAL
Intervention: Graded response item response theory
Number of subjects: 0
Study: 34138613

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34138816

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) ≥75th percentile (760.5 MET·min·wk-1) in early-to-mid second trimester
Number of subjects: 2388

Group type: EXPERIMENTAL
Intervention: Maintaining recommended levels of MVPA from preconception and first trimester through second trimester
Number of subjects: 2388

Group type: EXPERIMENTAL
Intervention: Maintaining sufficient activity throughout second trimester
Number of subjects: 2388

Group type: EXPERIMENTAL
Intervention: MVPA of at least 760.0 MET·min·wk-1 in early-to-mid second trimester
Number of subjects: 2388

Group type: EXPERIMENTAL
Intervention: Maintaining at least 500 MET·min·wk-1 from preconception through second trimester
Number of subjects: 2388
Study: 34138888

Group type: EXPERIMENTAL
Intervention: COVID-19 hospitalized patients
Number of subjects: 4704

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 4704

Group type: EXPERIMENTAL
Intervention: Respiratory rate
Number of subjects: 4704

Group type: EXPERIMENTAL
Intervention: Lactate dehydrogenase (LDH)
Number of subjects: 4704

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 4704

Group type: EXPERIMENTAL
Intervention: Creatinine values
Number of subjects: 4704
Study: 34139688

Group type: EXPERIMENTAL
Intervention: Intracardiac thrombus (ICT)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Atrial fibrillation (AF)
Number of subjects: 122
Study: 34139689

Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin (TcB) measurement
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin (TcB) measurement before phototherapy
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin (TcB) measurement after initiation of phototherapy
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin (TcB) measurement at the forehead
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin (TcB) measurement at the sternum
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin (TcB) measurement among infants born 24-28 weeks
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin (TcB) measurement among infants born 29-32 weeks
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin (TcB) measurement among infants born 33-35 weeks
Number of subjects: 296
Study: 34139747

Group type: EXPERIMENTAL
Intervention: OptiBP mobile application
Number of subjects: 91
Study: 34139864

Group type: EXPERIMENTAL
Intervention: Predilation during TAVR
Number of subjects: 0

Group type: COMPARATOR
Intervention: No predilation during TAVR (Control)
Number of subjects: 0
Study: 34140107

Group type: EXPERIMENTAL
Intervention: Triglyceride levels ≥150 mg/dl
Number of subjects: 3754

Group type: COMPARATOR
Intervention: Triglyceride levels
Number of subjects: 3754
Study: 34140212

Group type: EXPERIMENTAL
Intervention: Cortisol and ACTH concentrations measured in PMM2-CDG patients
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Hydrocortisone replacement and/or stress dosing during illness
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: ACTH low-dose stimulation test
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Upcoming stimulation testing planned
Number of subjects: 43
Study: 34140248

Group type: EXPERIMENTAL
Intervention: Onalespib plus erlotinib (erlotinib 150 mg orally every morning and onalespib 120 mg/m)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Onalespib plus erlotinib
Number of subjects: 11
Study: 34140311

Group type: EXPERIMENTAL
Intervention: Symptomatic AF group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Asymptomatic AF group
Number of subjects: 30
Study: 34140403

Group type: EXPERIMENTAL
Intervention: APX005M (0.03, 0.1, or 0.3 mg/kg i.v.) with cabiralizumab and nivolumab
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: APX005M (0.03, 0.1, or 0.3 mg/kg i.v.) with cabiralizumab without nivolumab
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nivolumab-containing regimens
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 26
Study: 34140482

Group type: EXPERIMENTAL
Intervention: Combination therapy of osimertinib and dacomitinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal dosing schedule for osimertinib and dacomitinib
Number of subjects: 0
Study: 34140586

Group type: EXPERIMENTAL
Intervention: Single moderate intensity bout of exercise intervention
Number of subjects: 60
Study: 34140638

Group type: EXPERIMENTAL
Intervention: CGM097 10-400 mg 3qw
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: CGM097 300-700 mg 3qw 2 weeks on/1 week off
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: CGM097
Number of subjects: 51
Study: 34141612

Group type: EXPERIMENTAL
Intervention: TP53 + RB1 co-mutation in pulmonary LCNEC patients
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: TP53 + RB1 co-mutation in extra-pulmonary LCNEC patients
Number of subjects: 322

Group type: COMPARATOR
Intervention: Comparison with small cell lung cancer (SCLC)
Number of subjects: 322
Study: 34141624

Group type: EXPERIMENTAL
Intervention: Pathogenic or clonal pathogenic HRR-only variants
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Clonal pathogenic variants in TP53 genes
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Pathogenic variants in HRR genes
Number of subjects: 501
Study: 34141717

Group type: EXPERIMENTAL
Intervention: High-Protein, Low Glycemic Index Diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Diet (not specified)
Number of subjects: 0
Study: 34142073

Group type: EXPERIMENTAL
Intervention: LCR1-LCR2 test
Number of subjects: 4903
Study: 34142085

Group type: EXPERIMENTAL
Intervention: Temozolomide
Number of subjects: 20
Study: 34142126

Group type: EXPERIMENTAL
Intervention: Finger systolic blood pressure (FSBP) measurement
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Digital-brachial pressure index (DBI) measurement
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intra/interday reproducibility of FSBP and DBI measurements
Number of subjects: 16
Study: 34142256

Group type: EXPERIMENTAL
Intervention: InSep (29-mRNA blood-based host response test)
Number of subjects: 397
Study: 34142315

Group type: EXPERIMENTAL
Intervention: Compliance with evidence-based clinical guidelines for the management of biliary acute pancreatitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation of new strategies based on identified gaps in compliance
Number of subjects: 0
Study: 34142350

Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg q2w)
Number of subjects: 1553

Group type: EXPERIMENTAL
Intervention: Dupilumab + TCS
Number of subjects: 1553

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1553

Group type: COMPARATOR
Intervention: Placebo + TCS
Number of subjects: 1553
Study: 34142595

Group type: EXPERIMENTAL
Intervention: Enhanced daycare of Traditional Chinese Medicine (TCM)
Number of subjects: 401
Study: 34143384

Group type: EXPERIMENTAL
Intervention: Prasugrel (n=43)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Ticagrelor (n=143)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Clopidogrel (n=94)
Number of subjects: 280
Study: 34143416

Group type: EXPERIMENTAL
Intervention: 50 mg eplerenone once daily
Number of subjects: 84

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 84
Study: 34143547

Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffold (BRS) implantation
Number of subjects: 3326
Study: 34143677

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34143682

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle education
Number of subjects: 0
Study: 34143867

Group type: EXPERIMENTAL
Intervention: Wrist-monitor (cuffless, wireless device)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cuff-based ABPM device
Number of subjects: 28
Study: 34143969

Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab
Number of subjects: 143
Study: 34143998

Group type: EXPERIMENTAL
Intervention: Fexinidazole 1800 mg once per day on days 1-4, then 1200 mg on days 5-10
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Fexinidazole
Number of subjects: 238
Study: 34144701

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS)
Number of subjects: 691
Study: 34144918

Group type: EXPERIMENTAL
Intervention: Farm-to-WIC intervention combining behaviorally focused instruction, handouts, farmers' market introduction, field trips, telephone coaching, and recipe demonstrations.
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Farm-to-WIC intervention
Number of subjects: 297

Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 297
Study: 34145168

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34145225

Group type: EXPERIMENTAL
Intervention: Idecabtagene vicleucel (ide-cel, bb2121)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Eligible RRMM (real-world outcomes)
Number of subjects: 190
Study: 34145677

Group type: EXPERIMENTAL
Intervention: 30-g FMT
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 60-g FMT
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: FMT
Number of subjects: 77
Study: 34145979

Group type: EXPERIMENTAL
Intervention: Mobocertinib (20 mg) with itraconazole (200 mg once daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mobocertinib (160 mg) with rifampin (600 mg once daily)
Number of subjects: 24
Study: 34145983

Group type: EXPERIMENTAL
Intervention: Ischaemic cardiomyopathy (ICM) group
Number of subjects: 496

Group type: COMPARATOR
Intervention: Non-ischaemic cardiomyopathy (NICM) group
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Propensity-score matched analysis
Number of subjects: 496
Study: 34146130

Group type: EXPERIMENTAL
Intervention: Diagnostic evaluation for EAS tumors
Number of subjects: 36
Study: 34146146

Group type: EXPERIMENTAL
Intervention: Double-layer barbed suture (fishbone suture)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34146238

Group type: EXPERIMENTAL
Intervention: Insulin-only configuration of the iLet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Default t
Number of subjects: 24
Study: 34146644

Group type: EXPERIMENTAL
Intervention: Oral metronidazole treatment for bacterial vaginosis
Number of subjects: 94

Group type: COMPARATOR
Intervention: Healthy women (no treatment mentioned)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Both groups (healthy women and women with BV)
Number of subjects: 94
Study: 34146655

Group type: EXPERIMENTAL
Intervention: 16 weeks of exercise training (45 min of intermittent cycling at 60% peak power output wattage)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Acute exercise (45 min of intermittent cycling at 60% peak power output wattage)
Number of subjects: 2
Study: 34146966

Group type: EXPERIMENTAL
Intervention: 4+ ACEs
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 2-3 ACEs
Number of subjects: 131
Study: 34147313

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg, intravenously, every 3 weeks for 3 courses)
Number of subjects: 10
Study: 34148211

Group type: EXPERIMENTAL
Intervention: ATTRv Glu89Gln amyloidosis patients from Bulgaria
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: ATTRv Glu89Gln amyloidosis patients from Italy
Number of subjects: 91
Study: 34148505

Group type: EXPERIMENTAL
Intervention: Intracranial stenting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34149034

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 0
Study: 34149383

Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention, details not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not specified.
Number of subjects: 0
Study: 34149468

Group type: EXPERIMENTAL
Intervention: Brief, group- and mosque-based intervention implemented by mosque leaders
Number of subjects: 0
Study: 34149587

Group type: EXPERIMENTAL
Intervention: Robotic Therapy (RT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional Therapy (CT)
Number of subjects: 44
Study: 34149627

Group type: EXPERIMENTAL
Intervention: Iscalimab
Number of subjects: 13